Mirum Pharmaceuticals, Inc. MIRM Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cash and cash equivalents, end of period of $326.64M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period increased by 53.9% year-over-year, from $212.25M to $326.64M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s cash and cash equivalents, end of period has grown at a 32.6% compound annual growth rate (CAGR), from $128M to $298.17M.